Tocainide Conjugation in Humans: Novel Biotransformation Pathway for a Primary Amine
作者:A.T. Elvin、J.B. Keenaghan、E.W. Byrnes、P.A. Tenthorey、P.D. McMaster、B.H. Takman、D. Lalka、C.V. Manion、D.T. Baer、E.M. Wolshin、M.B. Meyer、R.A. Ronfeld
DOI:10.1002/jps.2600690113
日期:1980.1
The metabolism of tocainide, an experimental antiarrhythmic drug, was studied in humans. Urinary excretion of unchanged drug was 28-55% in 24 hr after oral dosing. Urine hydrolysis with hydrochloric acid or beta-glucuronidase increased tocainide recovery to 55-79%. Saccharo-1,4-lactone inhibited the beta-glucuronidase-mediated tocainide recovery increase. Adjustment of urine to pH 13 produced a compound
在人体中研究了一种实验性抗心律失常药物托卡尼的代谢。口服给药后24小时尿未排泄药物排泄率为28-55%。用盐酸或β-葡糖醛酸糖苷酶水解尿液可使托卡尼德的回收率提高到55-79%。Saccharo-1,4-lactone抑制了β-葡萄糖醛酸苷酶介导的Tocainide回收率的增加。将尿液调节至pH 13产生了一种化合物,该化合物被鉴定为3-(2,6-二甲苯基)-5-甲基乙内酰脲。有证据表明,它来自相同的代谢产物,该代谢产物经过酸或β-葡萄糖醛酸苷酶处理后形成了额外的托卡尼特。Tocainide氨基甲酰基O-β-D-葡糖醛酸是为代谢物提出的结构。所建议的形成途径包括将二氧化碳添加到十氧萘胺的氨基氮中,然后将尿苷二磷酸-葡萄糖醛酸结合。